ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · Real-Time Price · USD
0.3774
-0.0081 (-2.10%)
At close: Oct 29, 2025, 4:00 PM EDT
0.3773
-0.0001 (-0.03%)
Pre-market: Oct 30, 2025, 4:42 AM EDT
ProPhase Labs Market Cap
ProPhase Labs has a market cap or net worth of $15.68 million as of October 29, 2025. Its market cap has decreased by -65.92% in one year.
Market Cap
15.68M
Enterprise Value
23.37M
1-Year Change
-65.92%
Ranking
Category
Stock Price
$0.38
Market Cap Chart
Since December 1, 1998, ProPhase Labs's market cap has decreased from $92.00M to $15.68M, a decrease of -82.96%. That is a compound annual growth rate of -6.36%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 28, 2025 | 16.00M | -11.60% |
| Dec 31, 2024 | 18.10M | -77.82% |
| Dec 29, 2023 | 81.60M | -47.96% |
| Dec 30, 2022 | 156.80M | 41.01% |
| Dec 31, 2021 | 111.20M | 4.41% |
| Dec 31, 2020 | 106.50M | 367.11% |
| Dec 31, 2019 | 22.80M | -37.36% |
| Dec 31, 2018 | 36.40M | 34.81% |
| Dec 29, 2017 | 27.00M | -21.05% |
| Dec 30, 2016 | 34.20M | 33.59% |
| Dec 31, 2015 | 25.60M | 13.27% |
| Dec 31, 2014 | 22.60M | -11.72% |
| Dec 31, 2013 | 25.60M | 26.73% |
| Dec 31, 2012 | 20.20M | 19.53% |
| Dec 30, 2011 | 16.90M | -3.98% |
| Dec 31, 2010 | 17.60M | -30.98% |
| Dec 31, 2009 | 25.50M | -50.58% |
| Dec 31, 2008 | 51.60M | -15.69% |
| Dec 31, 2007 | 61.20M | -15.24% |
| Dec 29, 2006 | 72.20M | -55.24% |
| Dec 30, 2005 | 161.30M | 64.42% |
| Dec 31, 2004 | 98.10M | -19.85% |
| Dec 31, 2003 | 122.40M | 94.29% |
| Dec 31, 2002 | 63.00M | 156.10% |
| Dec 31, 2001 | 24.60M | 179.55% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 735.25B |
| Johnson & Johnson | 450.17B |
| AbbVie | 402.67B |
| UnitedHealth Group | 333.04B |
| AstraZeneca | 259.35B |
| Novartis AG | 250.89B |
| Novo Nordisk | 235.38B |
| Abbott Laboratories | 221.28B |